Future Fields at PEGS Boston 2026
Turning drug discovery dead-ends into runways for development
Request a meetingJoin us in Boston from May 11-14 for PEGS Summit 2026
Future Fields’ EntoEngine™ uses transgenic Drosophila melanogaster to address protein production bottlenecks for drug discovery programs.
We look forward to connecting with industry leaders and sharing how the EntoEngine™ can fit into your protein production workflows.
Feature Presentation
Drug discovery is often stalled by limited access to crucial proteins. Common bottlenecks include the “scale-up cliff,” solubility, poor quality, and unstable clones. Traditional systems force trade-offs between speed, stability, and functionality, leaving critical projects shelved. Future Fields presents the EntoEngine™, a transgenic Drosophila-based platform designed to bypass these barriers. Through multiple case studies, attendees will learn how whole fruit flies can bring shelved projects back into development.
Compared to traditional recombinant protein production methods, our insect-based EntoEngine™:
- is 8X more cost effective
- is 1.7X faster
- has no genetic drift
- emits less GHGs and uses less water
Find us at booth #613
Our team will be stationed at the Omni Hotel conference hall from May 11-14. Whether you’re looking to scale your next-gen immunotherapy or explore an alternative expression system where conventional ones have failed, we’d love to connect.
Conference team:
- Matt Anderson-Baron, Co Founder & CEO
- Jeremy Jerasi, Sr. Business Development Representative
- Diane Jeon, Marketing Lead
- Daniel Nisakar, Marketing Associate
- Ashley Pillay, Digital Marketer
